Craig has received CURE’s inaugural Entrepreneur of the Year Award.
Craig Crews has been named a Fellow of the American Association for the Advancement of Science (AAAS) for “distinguished contributions to the field of chemical biology and particularly for contributions to the development of a new anticancer drug.”
Arvinas, Inc., a new biotech startup, is founded on the protein degradation technologies from the Crews Lab.
Carfilzomib/KyprolisTM, the next generation proteasome inhibitor developed in the Crews lab, received accelerated FDA approval for relapsed and refractory multiple myeloma.
GlaxoSmithKline announces a collaboration with the Crews lab to explore its PROTAC technology to control intracellular protein levels
Craig was selected as an Ellison Medical Foundation Senior Scholar in Aging
Leah Campbell successfully defended her doctoral thesis entitled Investigations of the Role of the Regeneration Epithelium during Axolotl Limb Regeneration
Anke Roth has joined the lab as a postdoc from Christoph Arenz’s lab, HU Berlin
Craig is invited to join the Editorial Advisory Board of ChemBioChem.
Craig has been appointed Gastprofessor at the Universität Konstanz.